← Back to front page
United States · Wires & real time · PR Newswire

IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in…

Published by PR Newswire · United States 24 min ago
IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in…
PR Newswire

Detailed summary

Single-arm extension cohort of approximately 90 refractory GEP-NEC patients to support potential accelerated approval, with ORR by BICR as the primary endpoint Randomized Phase 3…

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery, development and commercialization of transformative therapies to address unmet medical needs in cancer, today announced its registrational strategy for IDE849, a potential best-in-class delta-like ligand 3 (DLL3)-targeting Topo-I-payload antibody drug conjugate (ADC), in previously treated (2L+) neuroendocrine carcinomas (NEC). IDEAYA is planning to initiate registrational trials in both previously treated NEC and extensive-stage small cell lung cancer (ES-SCLC) by the end of the year.

"NEC is an aggressive disease with limited treatment options after first-line platinum-based chemotherapy. Our recent IDE849 data presented at ESMO in refractory NEC provides strong support for the clinical benefit that a DLL3-targeted ADC may offer for patients with this devastating disease," said Yujiro S. Hata, President and Chief Executive Officer of IDEAYA Biosciences. "In light of the fast-evolving landscape of DLL3-targeting agents we have completed two Type C meetings with the U.S.

Following a successful Type C meeting with the U.S. Food and Drug Administration (FDA) IDEAYA plans to advance a registrational development program for IDE849 in neuroendocrine carcinoma (NEC) by the end of 2026. The company intends to initiate a single-arm extension cohort within its ongoing Phase 1/2 clinical trial, enrolling approximately 90 previously treated patients with gastroenteropancreatic NEC (GEP-NEC). The cohort is intended to support a potential accelerated approval application, with a primary endpoint of confirmed overall response rate (ORR) assessed by blinded independent central review (BICR), supported by duration of response.

IDEAYA also plans to submit a protocol for a randomized, confirmatory Phase 3 trial of IDE849 in multiple NEC subtypes, including GEP-NEC and large cell NEC (LC-NEC), to support trial initiation by…

Opening of the article, excerpted from PR Newswire. To read the rest, open the article on the publisher's site.

Read the full article on PR Newswire Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.prnewswire.com)

Also worth reading